

## ASX Release

### Appendix 4C – Q2 2025 Quarterly Cash Flow Report

25 July 2025 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) ("Oneview" or "the Company"), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 30 June 2025 (Q2 25) and provided an update on business activities.

#### Financial Highlights

Oneview's cash balance at 30 June 2025 was €8.2 million (A\$14.7m) compared to €12.2 million (A\$21.0m) at 31 March 2025.

The Company had a net cash outflow of €4.0 million during the quarter compared to an outflow of €3.2 million in the same quarter of the prior year.

The Company had marginally higher operating spend (operating, staff and administrative & corporate costs) during the quarter compared to the same quarter of the prior year, including one-off restructuring costs of €234k following strategic decisions to reorganise certain aspects of the business. These primarily relate to the well-publicized adverse market conditions in the Australian private hospital sector, which have had a significant impact on the outlook for new sales and pricing in the Australian market.

The timing and quantum of R&D tax credit receipts also led to a material unfavourable variance in the quarter compared to the same quarter of the prior year. The R&D tax credit receipt for 2023 was €952k and was received in April 2024, whereas the R&D tax credit receipt for 2024 was €444k and was received in January 2025.

The higher outflows in the current quarter compared to the same quarter of the prior year were partially offset by higher cash receipts from customers of €2.1 million compared to €1.6 million in the same quarter of the prior year. Receipts from customers in the first half of the year were €6.4 million, up 51% compared to the first half of 2024.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees and salaries totalling €222,000 (A\$390,000).

## Operational Activities

### *Sales and Customer Updates*

The Company maintained strong momentum in adding new customers in the first half of 2025, securing two new customers through the Baxter sales channel. Willis Knighton Health is an 800-bed health system in Louisiana, and White Plains Hospital is a 300-bed facility in Westchester, New York. The sales pipeline remains robust, with multiple late-stage opportunities expected to close in the coming months, several of which could see live deployments before year-end.

The Company signed a three-year contract extension with one of its largest recurring revenue customers during the quarter. Taking account of additional bed deployments and price increases, we expect annual recurring revenue from this customer to increase by over 20% year-on-year.

Implementation projects progressed at our existing customer sites, including:

- Deployments of the core platform, the digital door sign and the digital whiteboard continued during the second quarter of 2025 at Inova Health under the 1,900-bed Master Services Agreement which was signed in April 2024, with deployments at Inova Fairfax and Inova Fair Oaks Hospital Innovation Unit.
- Oneview's core platform was deployed at The University of Iowa's North Liberty campus.
- Deployments at Mercy also continued in the quarter with 114 beds going live at Mercy Hospital Fort Smith in May 2025.
- Oneview's digital door sign was deployed at Sharp Grossmont in May 2025.
- The deployment project at the Rady Children's Health (formerly Children's Hospital of Orange County) progressed well during the quarter with 187 beds deployed in June 2025, with further deployments planned during the second half of the year.
- Oneview's core platform was also deployed at University of Miami's Kendall and Griffin Cancer Research Buildings, in the quarter, with further deployments scheduled at University of Miami in the coming months.
- Deployments commenced on one of Oneview's new customer logos, White Plains Medical Center, during the second quarter with further beds expected to go live during the second half of the year.

Upcoming Innovation:

- **Expansion of virtual care support:** To advance our smart patient room vision, we are expanding support for AI-powered virtual care platforms. In addition to existing integrations with Caregility and Teladoc, we are certifying care.ai and Artisight to offer customers a broader, best-in-class portfolio. By supporting diverse workflows, from virtual nursing to safety monitoring, this expansion enhances our ability to connect care teams and patients, anticipate risk, and orchestrate care delivery.
- **Next-generation personalization with MyStay and Ovie:** The new MyStay interface for TV and tablets, combined with the AI-powered care assistant "Ovie", will deliver enhanced personalization and proactive support for patients. The interface will support 50 languages, offer clear navigation, and adapt to different screen types. Ovie will provide tailored education, reminders, and support through natural interactions, enabling hands-free control for patients with limited dexterity.

- **Real-Time visibility and workflow coordination with the care experience portal:** This portal will give care teams real-time insights into patient engagement with the Oneview platform, including interactions with the AI-powered care assistant "Ovie". This will help identify patients needing additional support. With modular architecture and configurable role-based views, the portal will help hospitals improve satisfaction, streamline workflows, and deliver more responsive, personalized care.
- **Driving performance through data - KPI trending & benchmarking:** Oneview's new Trending & Benchmarking Dashboard will provide hospitals with longitudinal insights into patient engagement and system performance. This will help care teams monitor progress and compare performance against internal and peer group benchmarks. By aligning data insights with each organization's value plan, this capability will help hospitals identify opportunities, measure impact, and drive meaningful return on investment.

## Outlook

The Company has had a solid start to the year and continues to enjoy a very significant pipeline of new opportunities in our core market in the United States, both directly and via the Baxter channel, which now comprises over 180 opportunities. The maturity of the pipeline is developing at a solid pace and augurs well for the signing of new logos in the second half of 2025.

We continued to enhance our AI innovation strategy during the quarter, becoming the only vendor in our space and the first ASX listed company to achieve ISO42001 certification for its Artificial Intelligence Management System. We are not only setting a benchmark for the industry but also reinforcing our leadership in AI-powered healthcare innovation. This positions the Company to capitalise on emerging opportunities, while managing risks proactively and enhancing our operational resilience and competitive edge.

Where trust, safety, and ethical considerations are paramount, this certification assures our customers, partners, and shareholders that our AI solutions are built on a foundation of rigorous governance and ethical design.

Whilst the new US administrations changes to Medicaid funding have received widespread media attention, we have not seen any deterioration in market conditions in our US business at this time and look forward to the seasonally stronger second half with confidence.

As separately announced this morning, the Company will release its Half-Year Results for the six-month period ended 30 June 2025 on Wednesday 13th August 2025 and will host an investor and analyst conference call at 8am AEST on the same day.

**This announcement has been approved for release by the board of Oneview Healthcare plc.**

## About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams,

and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Oneview Healthcare PLC

**ABN**

610 611 768

**Quarter ended ("current quarter")**30<sup>th</sup> June 2025

<b>Consolidated statement of cash flows</b>		<b>Current quarter €'000</b>	<b>Year to date (6 months) €'000</b>
<b>1. Cash flows from operating activities</b>			
1.1 Receipts from customers		2,131	6,365
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		(1,401)	(2,812)
(c) advertising and marketing		(55)	(134)
(d) leased assets		-	-
(e) staff costs		(3,316)	(6,208)
(f) administration and corporate costs		(1,079)	(2,135)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		7	13
1.5 Interest and other costs of finance paid		-	-
1.6 Income taxes (paid)/refunded		-	(1)
1.7 Government grants and tax incentives		-	444
1.8 Other (working capital movements)		(91)	(594)
<b>1.11 Net cash from / (used in) operating activities</b>		<b>(3,804)</b>	<b>(5,062)</b>

<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(16)	(16)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(16)</b>	<b>(16)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	12,192	13,833
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(3,804)	(5,062)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(16)	(16)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	(181)	(564)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>8,191</b>	<b>8,191</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter €'000</b>	<b>Previous quarter €'000</b>
5.1	Bank balances	8,191	12,192
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>8,191</b>	<b>12,192</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter €'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	222
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

<b>7.</b>	<b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end €'000</b>	<b>Amount drawn at quarter end €'000</b>
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	<b>Total financing facilities</b>	-	-
7.5	<b>Unused financing facilities available at quarter end</b>	-	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8.</b>	<b>Estimated cash available for future operating activities</b>	<b>€'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,804)
8.2	Cash and cash equivalents at quarter end (item 4.6)	8,191
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	8,191
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	2.15
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/a	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/a	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		



## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....25 July 2025.....

Authorised by: ..... **BY THE BOARD** .....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.